Search
Tools content (print, share, increase/decrease text size):
-
Size
Middle area:Press releases 2013Press releases are intended to journalists, analysts and investors. Sanofi appoints David Loew, Senior Vice President, Commercial Operations, EuropeMay 23, 2013 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of MedicineMay 21, 2013 Sanofi announces the next steps of its Research site in Toulouse, FranceMay 17, 2013 Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in MyelofibrosisMay 17, 2013 Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)May 15, 2013 Combined General Shareholder Meeting of May 3, 2013May 03, 2013 Q1 2013 business EPS impacted by exclusivity losses in prior year. Growth platforms sales increased 8.6%May 02, 2013 Sanofi appoints two new Members to the Executive Committee to lead the new Commercial OrganizationMay 02, 2013 Sanofi and DNDi celebrate six years of collaboration in fighting malaria by distributing 200 million treatments of ASAQApril 25, 2013 Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC StudyApril 25, 2013 Sanofi Pasteur to Provide 1.7 Billion Doses of Oral Polio Vaccine from 2013 to 2017 for Polio EradicationApril 24, 2013 Hexyon/Hexacima 6-in-1 Pediatric Vaccine Approved in EuropeApril 22, 2013 Sanofi reinforces its presence in MoroccoApril 17, 2013 Sanofi strengthens its French-German partnership on the occasion the French-German Week for Science and AlumniApril 15, 2013 Sanofi and PATH announce the Launch of Large-scale Production of Semisynthetic Artemisinin against MalariaApril 11, 2013 Sanofi Pasteur’s New Quadrivalent Influenza Vaccine Accepted for Review for European ApprovalApril 11, 2013 Sanofi successfully prices USD 1.5 billion bond issueApril 04, 2013 Sanofi to Invest USD 75 million in a New Manufacturing Facility in VietnamMarch 29, 2013 Sanofi signs collaboration agreement with Schneider Electric to accelerate its energy efficiency program on its industrial sitesMarch 28, 2013 Sanofi and Transgene Announce Innovative Long-Term Collaboration for the Production of Immunotherapy TreatmentsMarch 25, 2013 Genzyme Receives Positive CHMP Opinion in the European Union for Once-daily, Oral AUBAGIO® to Treat Relapsing-Remitting Multiple SclerosisMarch 22, 2013 Effect of Genzyme’s LEMTRADA Maintained in Patients Beyond Two-Year Pivotal MS StudiesMarch 21, 2013 Genzyme’s Multiple Sclerosis Franchise Featured at AANMarch 13, 2013 Filing of the 2012 U.S. Form 20-F and French “Document de Référence" containing the Annual Financial ReportMarch 08, 2013 Composition of the Board of Directors of SanofiMarch 05, 2013 Sanofi and Regeneron Report Positive Proof-of-Concept Data for DupilumabMarch 02, 2013 Genzyme Receives Company Award from European Organisation for Rare Diseases (EURORDIS)February 27, 2013 European Medicines Agency Recommends Approval of Hexyon/Hexacima 6-in-1 Pediatric VaccineFebruary 22, 2013 Sanofi New Drug Application for Lixisenatide Accepted for Review by FDAFebruary 19, 2013 Genzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for Gaucher DiseaseFebruary 15, 2013 The Sanofi Espoir Foundation and the Union for International Cancer Control are extending their My Child Matters partnership for another three yearsFebruary 14, 2013 Sanofi delivers solid 2012 results despite patent expirationsFebruary 07, 2013 ZALTRAP® (aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal CancerFebruary 05, 2013 Once-Daily Lyxumia® (lixisenatide) Approved for Treatment of Type 2 Diabetes in EuropeFebruary 04, 2013 Genzyme and Isis Announce FDA Approval of KYNAMRO™ (mipomersen sodium) Injection for the Treatment of Homozygous Familial HypercholesterolemiaJanuary 29, 2013 Sanofi Announces Auvi-Q™, the First and Only Voice-Guided Epinephrine Auto-Injector, is Now Available in the U.S.January 28, 2013 Genzyme’s LEMTRADA™ (alemtuzumab) Application for MS Accepted for Review by the FDAJanuary 28, 2013 Sanofi Provides an Update on its Research & Development PipelineJanuary 08, 2013 Sanofi’s Chattem Acquires Over-the-Counter Antacid Rolaids®January 07, 2013 Sanofi Appoints Dr. Gary J. Nabel as Chairman of the Strategic Development and Scientific Advisory CouncilJanuary 07, 2013 |
Tools menu:
© Sanofi 2004-2013 - All rights reserved - Update: January 28, 2013
